AbbVie (ABBV) Reports 2.8% Yield; Baxter (BAX) Cuts Dividend
Published on Β· Source: finance.yahoo.com
AI Summary
Summarized by AI from the source belowAbbVie (ABBV) announced a quarterly dividend of $1.73 with a yield of 2.8%, extending its streak of increases since 2013. In contrast, Baxter (BAX) eliminated its dividend, reporting a net income loss of $900 million for FY2025, which disqualifies it from income-focused portfolios. AbbVie's revenue growth from Skyrizi and Rinvoq, at 31% and 23%, respectively, has helped offset losses from Humira and raised guidance for the year. The contrast between the two companies highlights the risks and potential for investors focused on income reliability and growth.
Informational only, not financial advice. Content is AI-generated and may contain errors. How this works.
About AbbVie Inc. (ABBV)
AbbVie is a research-based pharmaceutical company with a portfolio spanning immunology, oncology, and neuroscience.
The Health Care sector covers pharmaceutical, biotech, device and managed-care companies.
Earlier ABBV news
- Jefferies Recommends AbbVie (ABBV) as Quality Stock Amid AI Concerns
- AbbVie (ABBV) Hits New 52-Week High; Stock Up 40% Yearly
- AbbVie (ABBV) Acquires Apogee for $10.9 Billion Eczema Drug
- AbbVie (ABBV) Acquires Apogee for $10.9 Billion in Immunology Deal
- Dividend Portfolio Return: $43,770 Annual Income and $7,515 Tax Impact
Get the weekly market brief
One email every Monday: what moved, why, and what to watch. Free, unsubscribe anytime.
Get stories like this as they break
Our Telegram channel posts every market story the moment it is published. Free, and you can mute or leave anytime.
